CJC-1295 (With DAC) — 10mg
CJC-1295 (With DAC) is a synthetic peptide analog of growth hormone–releasing hormone (GHRH) engineered for research on long-acting endocrine signaling.
The “DAC” (Drug Affinity Complex) component allows the peptide to bind to albumin, extending its duration within experimental systems and enabling the study of prolonged receptor activity.
Researchers use CJC-1295 (With DAC) to investigate extended-release GHRH analog behavior, pituitary signaling cascades, and hormone-regulation modeling.
$199.99
-
Official retailer
-
Quality guaranteed
-
Free delivery from $99
-
Free returns is available
What Is CJC-1295 (With DAC)?
CJC-1295 (With DAC) is a synthetic peptide analog of growth hormone–releasing hormone (GHRH) engineered for research on long-acting endocrine signaling.
The “DAC” (Drug Affinity Complex) component allows the peptide to bind to albumin, extending its duration within experimental systems and enabling the study of prolonged receptor activity.
Researchers use CJC-1295 (With DAC) to investigate extended-release GHRH analog behavior, pituitary signaling cascades, and hormone-regulation modeling.
GENIQ provides this compound solely for controlled laboratory research, not for human or animal use.
Peptide Overview
CJC-1295 (With DAC) is used in research programs analyzing the effects of long-duration GHRH analogs.
Because of its extended activity profile, investigators often examine:
| • Prolonged GHRH receptor signaling |
| • Endocrine pathway modeling |
| • Multi-hour pituitary stimulation patterns |
| • cAMP-related intracellular responses |
| • Gene-expression activity associated with anabolic regulation |
| Its longer half-life compared to non-DAC variants makes it suitable for studying sustained biochemical signaling in vitro. |
All findings remain limited to preclinical and in-vitro experimental environments.
History of CJC-1295 (With DAC)
CJC-1295 was developed as part of endocrine-modulation research efforts aimed at creating GHRH analogs with improved duration for investigative purposes.
Scientists introduced the Drug Affinity Complex (DAC) modification to extend the peptide’s presence in the bloodstream of model systems by allowing reversible albumin binding.
The DAC-enabled design allowed researchers to differentiate between immediate-growth hormone–related signaling (seen with short-acting analogs) and long-duration endocrine communication.
As a result, CJC-1295 (With DAC) has been widely used in experiments exploring hormone regulation, receptor sensitivity, and prolonged pituitary activation patterns.
Peptide Structure
Sequence:
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Lys (with DAC modification)
Certificates of Analysis
CJC-1295 (With DAC) — 10mg
Research Findings
CJC-1295 (With DAC) has been used in research models exploring:
| • Extended endocrine signaling: Evaluating how long-acting GHRH analogs influence pituitary cell behavior. |
| • Albumin-binding dynamics: Studying how DAC modifications prolong the biological presence of peptides. |
| • Hormone-pulse simulation: Investigating multi-phase signaling curves compared to shorter analogs. |
| • Intracellular pathway modeling: Including cAMP activation and GH gene-transcription pathways. |
| • Comparative GHRH analog analysis: Assessing differences between DAC and non-DAC forms within controlled laboratory conditions. |
| These observations reflect non-clinical research only. |
These findings reflect laboratory experiments only and do not indicate clinical outcomes.
References
2. Lapchak P., et al. “Evaluation of CJC-1295 with and without DAC under controlled research conditions.” Peptide Endocrinology Research.
3. Hormone Research Group. “Albumin-binding strategies for extending peptide signaling.”
4. Peptide Dynamics Consortium. “Duration-based analysis of GHRH analogs in experimental environments.”
FAQ
What type of research is CJC-1295 (With DAC) used for?
It is used to study long-duration GHRH-related signaling, pituitary pathways, and extended endocrine activity.
Does GENIQ provide a Certificate of Analysis?
Yes. Every GENIQ research peptide is accompanied by a COA confirming purity and identity.
Is this peptide approved for human or animal use?
No. CJC-1295 (With DAC) is not FDA-approved and is not intended for human or veterinary application.
Can GENIQ provide instructions for dosing or reconstitution?
No. GENIQ does not provide any application or preparation guidance.
Who should handle this compound?
Only trained laboratory professionals within appropriate research facilities.
Research Use Only
All GENIQ compounds are intended strictly for laboratory research.
Not for human or animal consumption, medical use, or therapeutic application.
Nothing in this document should be interpreted as medical advice or as approval for use outside controlled scientific environments.
CJC-1295 (With DAC) is a synthetic peptide analog of growth hormone–releasing hormone (GHRH) engineered for research on long-acting endocrine signaling.
The “DAC” (Drug Affinity Complex) component allows the peptide to bind to albumin, extending its duration within experimental systems and enabling the study of prolonged receptor activity.
Researchers use CJC-1295 (With DAC) to investigate extended-release GHRH analog behavior, pituitary signaling cascades, and hormone-regulation modeling.
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.